-
Evaluating the Annual Cost of Progression in CD30+ Cutaneous T-cell Lymphomas Following 2L+ Systemic Treatment in Italy
Sep 9, 2025, 16:22 PM -
Influence of NICE Real-World Evidence Framework on HTA Submissions: Sensitivity Analyses in Real-World External Control Arm Studies
Sep 9, 2025, 16:22 PM -
Missing Health State Utility Values (HSUV) in NICE Oncology Appraisals: A Systematic Review of Utility Data Reporting and Handling Practices
Sep 9, 2025, 16:22 PM -
Budget Impact Analysis Of Migalastat Incorporation vs. Enzyme Replacement Therapies For Fabry Disease: Validation of a Cost-Assessment Tool In Brazilian Private Healthcare System
Sep 9, 2025, 16:22 PM -
Healthcare and Economic Impact of Friedreich's Ataxia in Italy: A Stratified Analysis Based On Patients’ Ambulatory Status
Sep 9, 2025, 16:22 PM -
Cost-Utility Analysis of the AlloMap® Test for the Monitoring of Patients After Heart Transplantation: Economic Evaluation Alongside the CUPIDON Trial
Sep 9, 2025, 16:22 PM -
Accelerating RTOR in Oncology: The AIM Model for Agile Trial Operations
Sep 9, 2025, 16:22 PM -
Matching-Adjusted Indirect Comparison Between Garadacimab and Donidalorsen for Long-Term Prophylaxis in Hereditary Angioedema
Sep 9, 2025, 16:22 PM -
Evaluation of Safety Signal Management in Europe: Insights From PRAC Reports (2016-2024)
Sep 9, 2025, 16:22 PM -
Evaluating the Conceptual Structure of the Barriers to Preexposure Prophylaxis (PrEP) Access Survey: A Confirmatory Item Factor Analysis
Sep 9, 2025, 16:22 PM -
Health-Related Quality of Life Following Administration of Influenza and COVID-19 Combination Vaccine in Older Adults: Results From a Phase 3 Randomized Controlled Trial
Sep 9, 2025, 16:22 PM -
Alternative Evidence Generation Approaches for Rare Diseases: Addressing HEOR and Healthcare Decision-Making Challenges
Sep 9, 2025, 16:22 PM -
Unlocking Insights in Prescription Data in England: The Power of the Prescribing Episode Statistics (PES) Database
Sep 9, 2025, 16:22 PM -
Dominance in Economic Evaluation as a Leverage in Pharmaceutical Price Negotiation
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness Analysis of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab for Patients With High-Risk Early Stage Triple-Negative Breast Cancer in Chile
Sep 9, 2025, 16:22 PM -
Indirect Costs Associated With Pneumococcal Disease: A Global Targeted Literature Review
Sep 9, 2025, 16:22 PM -
Cost-Effectiveness of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer Alongside the LIBELULE Randomized Phase III Trial
Sep 9, 2025, 16:22 PM -
Subcutaneous vs. Intravenous Administration in Oncology: A Literature Review of Impacts on Patients, Providers, and Hospitals
Sep 9, 2025, 16:22 PM -
Systematic Literature Review (SLR) of First-Line (1L) Treatments of Patients With Advanced or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma (GEA)
Sep 9, 2025, 16:22 PM -
Individual Therapy or No Therapy at All: Impact of Patient Individual Therapies As ACT in the German AMNOG Process
Sep 9, 2025, 16:22 PM
